Long Noncoding RNA P53-Stabilizing and Activating RNA Promotes P53 Signaling by Inhibiting Heterogeneous Nuclear Ribonucleoprotein K Desumoylation and Suppresses Hepatocellular Carcinoma.
Geng Qin,Xinyi Tu,Haibei Li,Pengbo Cao,Xi Chen,Jin Song,Hui Han,Yuanfeng Li,Bingqian Guo,Liting Yang,Pandeng Yan,Peiyao Li,Chengming Gao,Jinxu Zhang,Ying Yang,Jian Zheng,Huai-qiang Ju,Lei Lu,Xuan Wang,Chaohui Yu,Yi Sun,Baocai Xing,Hongzan Ji,Dongxin Lin,Fuchu He,Gangqiao Zhou
DOI: https://doi.org/10.1002/hep.30793
IF: 17.298
2019-01-01
Hepatology
Abstract:To identify hepatocellular carcinoma (HCC)-implicated long noncoding RNAs (lncRNAs), we performed an integrative omics analysis by integrating mRNA and lncRNA expression profiles in HCC tissues. We identified a collection of candidate HCC-implicated lncRNAs. Among them, we demonstrated that an lncRNA, which is named as p53-stabilizing and activating RNA (PSTAR), inhibits HCC cell proliferation and tumorigenicity through inducing p53-mediated cell cycle arrest. We further revealed that PSTAR can bind to heterogeneous nuclear ribonucleoprotein K (hnRNP K) and enhance its SUMOylation and thereby strengthen the interaction between hnRNP K and p53, which ultimately leads to the accumulation and transactivation of p53. PSTAR is down-regulated in HCC tissues, and the low PSTAR expression predicts poor prognosis in patients with HCC, especially those with wild-type p53. Conclusion: This study sheds light on the tumor suppressor role of lncRNA PSTAR, a modulator of the p53 pathway, in HCC.